<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467076</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD-NRN-0046</org_study_id>
    <secondary_id>U10HD040689</secondary_id>
    <secondary_id>U10HD021385</secondary_id>
    <secondary_id>U10HD027904</secondary_id>
    <secondary_id>U10HD027880</secondary_id>
    <secondary_id>U10HD034216</secondary_id>
    <secondary_id>U10HD040492</secondary_id>
    <secondary_id>U10HD053109</secondary_id>
    <secondary_id>U10HD040461</secondary_id>
    <secondary_id>U10HD068263</secondary_id>
    <secondary_id>U10HD068270</secondary_id>
    <secondary_id>U10HD068278</secondary_id>
    <secondary_id>U10HD036790</secondary_id>
    <nct_id>NCT01467076</nct_id>
  </id_info>
  <brief_title>Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)</brief_title>
  <official_title>Pilot Randomized Clinical Trial of Inhaled PGE1 in Neonates With Sub-Optimal Response to Inhaled Nitric Oxide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Neonatal Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Neonatal Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial (RCT) on the use of Inhaled prostaglandin E1 (IPGE1) in
      Neonatal Hypoxemic Respiratory Failure (NHRF). Fifty patients recruited at 10 high volume
      sites within the NICHD Neonatal Research Network will constitute a pilot sample to evaluate
      the feasibility and safety of prolonged IPGE1 administration and determination of optimal
      dose. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over
      a maximum duration of 72 hours and compared with placebo. Once feasibility and safety of
      IPGE1 administered over 72 hours has been demonstrated in the pilot trial, a full scale
      randomized controlled trial will be planned.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypoxemic respiratory failure in the newborn (NHRF) is usually associated with widespread
      vasoconstriction of the pulmonary microvasculature giving rise to intra- and extra-pulmonary
      shunts and profound hypoxemia. The goal of therapy is to decrease the regional pulmonary
      vascular resistance of ventilated lung areas thus decreasing intrapulmonary shunting and
      selectively reducing the pulmonary-artery pressure without causing systemic vasodilation.
      Intravenously administered vasodilators lack pulmonary selectivity leading to systemic side
      effects. Inhaled nitric oxide (INO), a selective pulmonary vasodilator, has revolutionized
      the treatment of respiratory failure in the newborn. However, there is lack of sustained
      improvement in 30-46% of infants; moreover, INO requires specialized systems for
      administration, making the treatment expensive. Aerosolized prostaglandins I2 and E1 have
      been reported to be effective selective pulmonary vasodilators in animals and human adults.
      In addition, inhaled prostaglandin I2 (IPGI2) has also been reported to be effective in
      preterm and term newborns, and children with pulmonary hypertension. Although intravenous
      PGE1 is widely used in neonates, the use of the inhaled form has not been reported in
      newborns with pulmonary hypertension. Compared to PGI2, PGE1 has a shorter half-life, lower
      acidity constant (pKa) (6.3 versus 10.5), bronchodilator action, anti-proliferative and
      anti-inflammatory effects on the alveolar, interstitial and vascular spaces of the lung.
      Prostaglandin nebulization can be used without the sophisticated technical equipment needed
      for controlled NO inhalation and hence is less expensive. It has no known toxic metabolites
      or toxic effects. Prostaglandins and nitric oxide (NO) relax the vascular smooth muscles
      through two different second-messenger systems; therefore, in combination, INO and IPGE1 may
      have synergistic effect. The existing literature suggests that inhaled PGE1 is a potential
      effective vasodilator in the treatment of NHRF . We have reported the safety and feasibility
      of short-term administration of inhaled PGE1 in an un-blinded Phase I/II dose-escalation
      study. Four doses ranging from 25 to 300 ng/kg/min were tested for a maximum duration of 3
      hours. We have also reported the stability of IPGE1, its emitted dose and aerosol particle
      size distribution (APSD) in a neonatal ventilator circuit. In addition we have demonstrated
      the safety of high dose IPGE1 (1200 ng/kg/min) over 24 hours in ventilated piglets. In the
      current protocol, we propose a pilot to evaluate the feasibility and safety of prolonged
      IPGE1 in NHRF. Two doses of IPGE1 (300 and 150 ng/kg/min) will be tested followed by weaning
      for a maximum duration of 72 hours to determine feasibility, safety, optimal dose and
      duration of therapy in 50 patients in ten NICHD NRN sites. An IND status has been approved by
      the FDA for this trial.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was halted due to futility concerns based on the unmet benchmarks as specified in the
    pilot study protocol.
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Feasibility to Recruit at Least 50 Infants</measure>
    <time_frame>9 months after 75% of the participating sites are enrolling</time_frame>
    <description>The primary outcome is the ability to recruit adequate number of infants (n=50) in a 9 month period without excessive (&gt;20%) protocol violations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Partial Pressure of Oxygen in the Blood (PaO2)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Oxygenation Index (OI)</measure>
    <time_frame>72 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for INO 72 Hours After INO</measure>
    <time_frame>72 hours after INO</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of iNO Therapy</measure>
    <time_frame>Until death or hospital discharge, up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Extracorporeal Membrane Oxygenation (ECMO)</measure>
    <time_frame>Until death or hospital discharge, up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>Until death or hospital discharge, up to on year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Oxygen (O2) Used, and Need for Supplemental Oxygen (O2)</measure>
    <time_frame>28 Days of LIfe</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Up to one year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Prematurity</condition>
  <condition>Respiratory Insufficiency</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <arm_group>
    <arm_group_label>Inhaled PGE1 (150 ng/kg/min)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 ng/kg/min Inhaled PGE1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible infants will be randomly assigned to either IPGE1 [150ng/kg/min], IPGE1 [300ng/kg/min] or control group. Infants in the control group will receive the same volume of aerosolized saline and oxygen from the respirator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PGE1 (300 ng/kg/min)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 ng/kg/min of Inhaled PGE1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aerosolized Normal Saline</intervention_name>
    <description>Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.</description>
    <arm_group_label>Aerosolized Normal Saline</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled PGE1</intervention_name>
    <description>Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.</description>
    <arm_group_label>Inhaled PGE1 (150 ng/kg/min)</arm_group_label>
    <arm_group_label>Inhaled PGE1 (300 ng/kg/min)</arm_group_label>
    <other_name>Inhaled Prostaglandin E1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age less than or equal to 34 weeks

          -  Postnatal age less than or equal to 7 days (168 hours).

          -  Assisted ventilation for hypoxemic respiratory failure.

          -  Diagnosis of NHRF including perinatal aspiration syndrome (meconium, blood, or
             amniotic fluid), suspected/proven pneumonia/sepsis, respiratory distress syndrome,
             idiopathic persistent pulmonary hypertension of the newborn (PPHN) or suspected
             pulmonary hypoplasia.

          -  Receiving INO for at least 1 hour and not &gt;72 hours.

          -  Oxygenation Index (OI ) ≥ 15 on any 2 arterial blood gases 15 minutes to 12 hours
             apart while on INO.

          -  An indwelling arterial line is present

        Exclusion Criteria:

          -  Any infant in whom a decision has been made not to provide full treatment (e.g.
             chromosomal anomalies, severe birth asphyxia).

          -  Known structural congenital heart disease except patent ductus arteriosus and
             atrial/ventricular level shunts.

          -  Congenital diaphragmatic hernia.

          -  Thrombocytopenia unresponsive to platelet transfusion.

          -  Enrollment in a conflicting and/or Investigational New Drug (IND) clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beena Sood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Keszler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University, Women &amp; Infants Hospital of Rhode Island</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. Michael Cotten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abhik Das, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krisa P Van Meurs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Namasivayam Ambalavanan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan M Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin Ohls, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo J Sanchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas, Southwestern Medical Center at Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Satyan Lakshminrusimha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uday Devaskar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leif Nelin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute at Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University, Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://neonatal.rti.org/</url>
    <description>Neonatal Research Network</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <results_first_submitted>November 3, 2016</results_first_submitted>
  <results_first_submitted_qc>November 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2016</results_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Opened for recruitment on 10/20/2011. There was a lag of 33 to 90 days between IRB approval and site readiness to enroll patients. 46 infants were screened at 8 sites, 14 met eligibility criteria, and 7 were randomized. Enrollment was halted for lack of feasibility in mid-May 2012; at that time, only 7 patients had been enrolled.</recruitment_details>
      <pre_assignment_details>Seven eligible infants were not enrolled because parents were unavailable or refused consent for 3 of the infants, 3 infants met ECMO criteria, and 1 had cardio-respiratory arrest.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Aerosolized saline</description>
        </group>
        <group group_id="P2">
          <title>Low Dose IPGE1</title>
          <description>150 ng/kg/min</description>
        </group>
        <group group_id="P3">
          <title>High Dose IPGE1</title>
          <description>300 ng/kg/min</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Infants randomized to the Control group were given the placebo dose.
Infants randomized to the Low Dose IPGE1 were given the lower dose.
Infants randomized to the High Dose IPGE1 were given the higher dose.</population>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Aerosolized saline</description>
        </group>
        <group group_id="B2">
          <title>Low Dose IPGE1</title>
          <description>150 ng/kg/min</description>
        </group>
        <group group_id="B3">
          <title>High Dose IPGE1</title>
          <description>300 ng/kg/min</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age at Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.75" lower_limit="27.80" upper_limit="58.33"/>
                    <measurement group_id="B2" value="11.30" lower_limit="7.10" upper_limit="15.50"/>
                    <measurement group_id="B3" value="26.65" lower_limit="10.28" upper_limit="43.03"/>
                    <measurement group_id="B4" value="28.73" lower_limit="7.10" upper_limit="58.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birthweight</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3591" lower_limit="2880" upper_limit="3965"/>
                    <measurement group_id="B2" value="3530" lower_limit="3470" upper_limit="3590"/>
                    <measurement group_id="B3" value="3320" lower_limit="3103" upper_limit="3537"/>
                    <measurement group_id="B4" value="3496" lower_limit="2880" upper_limit="3965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Delivery by Cesarean Section</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intubation in Delivery Room</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assess Feasibility to Recruit at Least 50 Infants</title>
        <description>The primary outcome is the ability to recruit adequate number of infants (n=50) in a 9 month period without excessive (&gt;20%) protocol violations.</description>
        <time_frame>9 months after 75% of the participating sites are enrolling</time_frame>
        <population>Late preterm &amp; term infants ≤ 7 days postnatal age undergoing conventional ventilation (CNV) or high frequency oscillatory ventilation (HFOV) for NHRF (including perinatal aspiration syndrome, suspected/proven pneumonia/sepsis, respiratory distress syndrome, idiopathic PPHN or suspected pulmonary hypoplasia) with suboptimal response to INO</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Aerosolized saline</description>
          </group>
          <group group_id="O2">
            <title>Low Dose IPGE1</title>
            <description>150 ng/kg/min</description>
          </group>
          <group group_id="O3">
            <title>High Dose IPGE1</title>
            <description>300 ng/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Feasibility to Recruit at Least 50 Infants</title>
          <description>The primary outcome is the ability to recruit adequate number of infants (n=50) in a 9 month period without excessive (&gt;20%) protocol violations.</description>
          <population>Late preterm &amp; term infants ≤ 7 days postnatal age undergoing conventional ventilation (CNV) or high frequency oscillatory ventilation (HFOV) for NHRF (including perinatal aspiration syndrome, suspected/proven pneumonia/sepsis, respiratory distress syndrome, idiopathic PPHN or suspected pulmonary hypoplasia) with suboptimal response to INO</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Partial Pressure of Oxygen in the Blood (PaO2)</title>
        <time_frame>72 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Oxygenation Index (OI)</title>
        <time_frame>72 Hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for INO 72 Hours After INO</title>
        <time_frame>72 hours after INO</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of iNO Therapy</title>
        <time_frame>Until death or hospital discharge, up to one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <time_frame>Up to one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Extracorporeal Membrane Oxygenation (ECMO)</title>
        <time_frame>Until death or hospital discharge, up to one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Mechanical Ventilation</title>
        <time_frame>Until death or hospital discharge, up to on year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Oxygen (O2) Used, and Need for Supplemental Oxygen (O2)</title>
        <time_frame>28 Days of LIfe</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>Up to one year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Enrolled infants were monitored continuously throughout study aerosol administration and through 48 hours post study aerosol discontinuation for possible adverse effects of PGE1.</time_frame>
      <desc>Monitored adverse events (AEs) include arrhythmia, hypotension, seizures, bleeding tendency, diarrhea, and seizures. 2 AEs reported; neither was attributed to study aerosol. One infant in control group developed transient, self-resolved mild fever within 5 minutes of starting study aerosol, and completely resolved within 6 hours of onset. One infant in control group developed moderate hypotension 66 hours after initiation of study aerosol, which completely resolved within an hour of onset.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Aerosolized saline</description>
        </group>
        <group group_id="E2">
          <title>Low Dose IPGE1</title>
          <description>150 ng/kg/min</description>
        </group>
        <group group_id="E3">
          <title>High Dose IPGE1</title>
          <description>300 ng/kg/min</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Adverse Event Form</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>New onset bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>New onset seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators must adhere to the Neonatal Research Network Publication policies.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Beena Sood, M.D.</name_or_title>
      <organization>Wayne State University</organization>
      <phone>313-745-5638</phone>
      <email>bsood@med.wayne.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

